4967 — Kobayashi Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥400bn
- ¥321bn
- ¥173bn
- 92
- 36
- 27
- 51
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 158,340 | 150,514 | 155,252 | 166,258 | 173,455 |
Cost of Revenue | |||||
Gross Profit | 90,976 | 85,266 | 88,774 | 92,331 | 96,376 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 134,554 | 125,859 | 129,646 | 139,912 | 147,823 |
Operating Profit | 23,786 | 24,655 | 25,606 | 26,346 | 25,632 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 26,804 | 26,635 | 27,636 | 27,950 | 27,559 |
Provision for Income Taxes | |||||
Net Income After Taxes | 19,139 | 19,205 | 19,716 | 20,023 | 20,338 |
Net Income Before Extraordinary Items | |||||
Net Income | 19,139 | 19,205 | 19,716 | 20,023 | 20,338 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 19,139 | 19,205 | 19,715 | 20,022 | 20,338 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 262 | 262 | 267 | 276 | 285 |
Dividends per Share |